Search

Copyright of BJS Open is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: Large population-based studies give insight into the prognosis and treatment outcomes of patients with pancreatic neuroendocrine tumors (pNETs). Therefore, we provide an overview of the treatment and related survival of pNET in the Netherlands. Methods: Patients diagnosed with pNET between 2008 and 2013 from the Netherlands Cancer Registry were included. Patient, tumors and treatment characteristics were reported. Survival analyses with log-rank testing were performed to compare survival. Results: In total, 611 patients were included. Median follow-up was 25.7 months, and all-cause mortality was 42%. Higher tumor grade and TNM stage were significantly associated with worse survival in both the overall and metastasized population. The effect of distant metastases on survival was more significant in lower tumor stages (T1-3 p < 0.05, T4 p = 0.074). Resection of the primary tumor was performed in 255 (42%) patients. Patients who underwent surgery had the highest 5-year survival (86%) compared to PRRT (33%), chemotherapy (21%), targeted therapy and somatostatin analogs (24%) (all p < 0.001). Patients with T1M0 tumors ( n = 115) showed favorable survival after surgical resection ( N = 95) compared to no therapy ( N = 20, p = 0.008). Resection also improved survival significantly in patients with metastases compared to other treatments (all p > 0.05). Without surgery, PRRT showed the best survival curves in patients with distant metastases. Grade 3 tumors and surgical resection were independently associated with survival (HR 7.23 and 0.12, respectively). Conclusion: Surgical resection shows favorable outcome for all pNET tumors, including indolent tumors and tumors with distant metastases. Prospective trials should be initiated to confirm these results. [ABSTRACT FROM AUTHOR]

ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/ UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing. [ABSTRACT FROM AUTHOR]

The article presents a case study of 64-year-old woman with a history of hypertension, steatotic hepatitis and hypercholesterolaemia.

B Background: b Efficacy of treatment of pancreatic neuroendocrine tumors (pNET) requires experience and knowledge. Without surgery, patients with DM had better survival with systemic treatment than without treatment (28% vs 15%, p=0.015); independent of tumor stage (T1-2 vs T3-4, p<0.001). LNM, DM, surgery, targeted therapy and nuclear therapy were independently associated with better survival for patients with G1 and G2 tumors. [Extracted from the article]

B Background: b Urgical resection is the preferred treatment for non-functioning pancreatic neuroendocrine tumors (NF-pNET), however recurrence still occurs frequently after curative surgery, worsening prognosis of patients. We present the recurrence-score to predict recurrence after curative resection of NF-pNET. The recurrence-score was developed using independent predictors for recurrence to predict recurrence within 5-years after curative resection. [Extracted from the article]

B Background: b Follow-up after curative surgery for pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence, however reliable recurrence rates are difficult to deduct from literature. B Methods: b Literature search was performed on studies reporting recurrence after complete resection of grade 1 or 2 pNET without distant metastases or hereditary syndromes. Factors associated with worse disease free survival included: tumor size, tumor grade, lymph node metastases, perineural invasion and R1 resection. [Extracted from the article]